🇺🇸 FDA
Pipeline program

Alvelestat (MPH966)

IRB-300002338

Phase 2 small_molecule completed

Quick answer

Alvelestat (MPH966) for Alpha-1 Antitrypsin Deficiency (AATD) is a Phase 2 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Mereo BioPharma Group plc
Indication
Alpha-1 Antitrypsin Deficiency (AATD)
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials